Literature DB >> 10340544

Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2.

M R Machein1, W Risau, K H Plate.   

Abstract

Malignant gliomas are a prominent target for cancer gene therapy approaches because of their poor prognosis despite all currently available therapies. Gene therapy strategies developed to interfere with the normal function of vascular endothelial growth factor receptors have been successfully used in different experimental models to block tumor angiogenesis and to inhibit tumor growth. In this study we examined whether retroviruses encoding a mutant VEGF receptor 2 (VEGFR-2) could suppress tumor angiogenesis and thereby prolong the survival of rats bearing syngeneic intracerebral glioma tumors. Survival time of rats with intracerebral tumors was significantly prolonged in a dose-dependent manner when retroviruses carrying a VEGFR-2 mutant were cotransplanted with tumor cells. No effect on survival was observed in rats that received virus-producing cells or virus supernatant intracerebrally after 5 days of tumor injection. In established subcutaneous tumors treatment with multiple injections of virus-producing cells also inhibited tumor growth in a dose-dependent manner. After implantation of tumor cells stably transfected with a truncated form of VEGFR-2, rats exhibited a rate of survival similar to that of animals treated with high numbers of virus-producing cells encoding the truncated form of VEGFR-2. Morphologically, tumors showed signs of impaired angiogenesis, such as extensive necrosis and reduced tumor vascular density. These results suggest a dual mode of function of truncated VEGFR-2, namely dominant-negative inhibition of VEGFR-2 function and VEGF depletion by receptor binding. We further explored the safety of retrovirus-mediated gene transfer. Although virus sequences were found in different tissues after intracerebral injection of virus-producing cells, no morphological changes were observed in any tissue after a follow-up time of 6 months. Our results indicate that VEGFR-2 inhibition is useful for the treatment of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340544     DOI: 10.1089/10430349950018111

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  13 in total

1.  Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport.

Authors:  K Ozawa; T Kondo; O Hori; Y Kitao; D M Stern; W Eisenmenger; S Ogawa; T Ohshima
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model.

Authors:  F Griscelli; H Li; C Cheong; P Opolon; A Bennaceur-Griscelli; G Vassal; J Soria; C Soria; H Lu; M Perricaudet; P Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Models for assessment of angiogenesis in gliomas.

Authors:  R H Goldbrunner; S Wagner; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 4.  VEGF in brain tumors.

Authors:  M R Machein; K H Plate
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Antiangiogenic Gene Therapy in Cancer.

Authors:  L Zhang; Q R Chen; A J Mixson
Journal:  Curr Genomics       Date:  2000       Impact factor: 2.236

Review 6.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 7.  Potential applications of gene therapy in the patient with cancer.

Authors:  P W Szlosarek; A G Dalgleish
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

8.  Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model.

Authors:  Marcia Regina Machein; Anette Knedla; Rolf Knoth; Shawn Wagner; Elvira Neuschl; Karl H Plate
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 9.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

Review 10.  The emerging role of anti-angiogenic therapy for malignant glioma.

Authors:  David A Reardon; Annick Desjardins; Jeremy N Rich; James J Vredenburgh
Journal:  Curr Treat Options Oncol       Date:  2008-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.